PHGE is set to present data from its Phase 1b/2a study for BX004 at the North American Cystic Fibrosis Conference in Boston on Sept. 27 and Sept. 28.

Vitamin D is linked to a 34% reduction in the relative risk for disease activity in patients with clinically isolated ...

When states legalize medical and recreational cannabis, fewer prescriptions for anxiety are filled, but more for depression ...

The FDA announced earlier today that ilunocitinib tablets (Zenrelia; Elanco) has received its approval. The latest drug from ...

Opioids, potent pain relievers for patients with cancer, frequently cause constipation, which is a significant issue.

An NIH-supported clinical trial of pomalidomide in treating hereditary hemorrhagic telangiectasia stopped early due to ...

Three months of supplementation with a prebiotic blend of inulin and oligofructose may significantly improve measures of ...

The combined 2% rewards rate — 1% when you make a purchase and 1% when you pay it off — is among the best on any cash-back card, especially for an annual fee of $0. Many or all of the products ...

ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured ...

Insilico Medicine has announced positive preliminary results from its Phase IIa clinical trial of ISM001-055, a small ...

The blinded blood pressure monitor and scale allows blind data monitoring, where participants can take readings but not see ...

Gefapixant decreased cough-induced stress urinary incontinence (CSUI) episodes in women with refractory/unexplained chronic cough and CSUI.